difference between sglt2 and glp 1 Recommendations for SGLT2i versus GLP-1 RA on the basis of kidney Summary of cardiovascular outcome trials

Metabolic dysfunction is at the root of many chronic diseasesincluding type 2 diabetes, fatty liver disease (NAFLD), cardiovascular disease, and even certain cancers

M-9/GN/AP/96/C/R.

Major adverse cardiovascular events were also lower in patients on a GLP-1 RA (14.9% vs 18.5%

These bacteria thrive on sulfur-containing amino acids found in proteins, cruciferous vegetables, and certain dairy products

548 Phase II trials of olpasiran [OCEAN(a)-DOSE] (NCT04270760) showed that a higher dose (75 or 225 mg) could reduce the Lp(a) level of patients by more than 95% compared with the placebo

Experienced Registered Dietitian Rita Faycurry, RD, notes, "Some people may be at a higher risk of gaining weight on Lexapro